DEP irinotecan combination outperforms in refractory human colon cancer model
(WorldNews Business)

DEP® irinotecan combination outperforms in refractory human colon cancer model DEP® irinotecan, a proprietary nanoparticle formulation, in combination with cetuximab (Erbitux®) showed complete suppression of tumour growth and 100% survival in an irinotecan-refractory human colon cancer model The significant antitumor effect induced by DEP® irinotecan was despite the fact that leading colon cancer treatments, irinotecan (Camptosar®) and Erbitux®, showed limited activity in this human colon cancer model This study builds on previously announced promising efficacy data for DEP® irinotecan in human colon and pancreatic cancer models Starpharma is currently completing final trial preparations for...